Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Autocrat
London, United Kingdomautolus.com ↗
- Ownership
- Private
- Employees
- ~500
- Development stage
- Other
01
Overview
Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T-cell therapies for the treatment of cancer and autoimmune diseases. The company utilizes a proprietary suite of T-cell programming technologies to engineer precisely targeted, controlled, and highly active T-cell products. Its lead candidate, obe-cel (Aucatzyl), recently received FDA approval for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Autolus aims to provide curative treatments with improved safety profiles compared to first-generation CAR-T therapies.
- Therapeutic areas
- Oncology
- Modalities
- CAR-T cell therapyCell therapy
- Industry
- Biotech
02
Partnerships
Beyond the preview
Go deeper on Autocrat.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Autocrat.